Sign in
II

Invivyd, Inc. (IVVD)·Q2 2025 Earnings Summary

Executive Summary

  • Q2 2025 net product revenue was $11.8M, up 413% year-over-year but below Street; EPS of -$0.12 missed consensus, and revenue fell short versus $23.2M consensus, driving a negative surprise and stock pressure. The company cited “modest” PEMGARDA growth in a period of low COVID transmission and reiterated near‑term profitability remains possible with the respiratory virus season .
  • Consensus comparison: Revenue $11.8M vs $23.2M estimate; EPS -$0.12 vs -$0.023, both misses; 3 estimates underpin the consensus for each metric (S&P Global) [Values retrieved from S&P Global].
  • Strategic catalyst: alignment with FDA on a rapid BLA pathway for VYD2311 via a single Phase 2/3 trial with a 12‑week primary endpoint; observed IM half‑life of ~76 days supports potential long‑duration protection .
  • Liquidity/opex discipline: cash & equivalents $34.9M at 6/30/25, SVB term loan facility up to $30M available; total operating costs and expenses reduced sequentially (Q2: $26.8M vs Q1: $28.2M) .
  • Additional near‑term milestones: RSV candidate identification expected in Q3 2025 and preclinical measles mAb candidate by YE25; Long COVID SPEAR Study Group launched in July 2025 .

What Went Well and What Went Wrong

  • What Went Well

    • Strong FDA engagement: alignment on a rapid path to full approval (BLA) for VYD2311 with a compact Phase 2/3 design (12‑week primary endpoint) potentially enabling rapid enrollment .
    • Promising VYD2311 data: attractive safety profile across routes and an observed IM half‑life of ~76 days; dose modeling suggests strong protection with IM dosing on long intervals .
    • Cost control and liquidity: sequential opex reduction and $34.9M cash at quarter‑end with an option for $30M non‑dilutive term loan capacity from SVB .

  • What Went Wrong

    • Topline miss vs Street: Q2 revenue of $11.8M significantly undershot consensus $23.2M; EPS -$0.12 missed consensus -$0.023 (S&P Global), indicating slower uptake in a low transmission quarter [Values retrieved from S&P Global].
    • Profitability timing: target of near‑term profitability in 1H 2025 was not met; management attributes timing to seasonal dynamics and growth pacing of base business .
    • Sequential momentum: revenue grew modestly versus Q1 ($11.3M to $11.8M), and Street expected stronger adoption; analysts will question commercialization velocity and payer/access pathways despite guideline support .

Financial Results

MetricQ2 2024Q1 2025Q2 2025
Revenue ($USD Millions)$2.264 $11.304 $11.786
Net Loss ($USD Millions)$(47.247) $(16.289) $(14.660)
EPS (Basic & Diluted, $USD)$(0.40) $(0.14) $(0.12)
Total Operating Costs & Expenses ($USD Millions)$51.511 $28.226 $26.846
Cost of Product Revenue ($USD Millions)$0.088 $0.834 $0.685
Cash & Equivalents at Period End ($USD Millions)N/A$48.078 $34.905
  • Segment breakdown: Not applicable; reported net product revenue is driven by PEMGARDA (pemivibart) .

KPIs (commercial footprint and execution)

  • Guideline adoption and footprint
    • PEMGARDA added to NCCN Clinical Practice Guidelines in Oncology for B‑Cell Lymphomas; IDSA recommends PEMGARDA PrEP in moderately/severely immunocompromised individuals ≥12 years .
  • Field activity metrics (as of Apr 30, 2025)
    • Infusion sites offering PEMGARDA: 880; Reordering accounts: 479; HCP interactions: >11,500; Called-on unique accounts: 642 .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Profitability target1H 2025Near‑term profitability targeted by end of 1H 2025 Target not met; remains possible with upcoming respiratory virus season and continued opex moderation Timing delayed / maintained qualitatively
VYD2311 regulatory path2025Phase 1 data anticipated later in Q2 2025; advancing regulatory engagement; manufacturing substantially completed Aligned with FDA on rapid BLA pathway; single Phase 2/3 RCT, 12‑week primary endpoint; planned IND and protocol finalization; optional head‑to‑head safety vs vaccine Raised (clarified path and timeline)
RSV program2025Update expected by end of 2025 Update on RSV candidate identification anticipated in Q3 2025 Pulled forward
Measles program2025Progress update expected by end of 2025 Preclinical measles mAb candidate identification by end of 2025 Maintained / clarified
Operating expenses2025Ongoing reductions expected (manufacturing spend lower) Sequential reduction achieved in Q2; continued discipline planned Maintained execution focus

Earnings Call Themes & Trends

TopicPrevious Mentions (Q4 2024, Q1 2025)Current Period (Q2 2025)Trend
Regulatory/legalFDA declined PEMGARDA treatment EUA in Feb 2025; company re-engaging, submitted response and citizen petition Alignment with FDA on rapid BLA pathway for VYD2311; single Phase 2/3, 12‑week endpoint; planned head‑to‑head safety vs vaccine Positive regulatory momentum
Product performanceQ4 2024 PEMGARDA revenue grew 48% q/q to $13.8M; Q1 2025 $11.3M with sales force internalization and early signs of Q2 acceleration Q2 2025 revenue $11.8M; management described “modest” growth amid low transmission; base business growing with expanded in‑house field presence Sequential modest growth; momentum building into seasonality
R&D executionVYD2311 Phase 1 data positive; average 17‑fold greater in vitro potency vs pemivibart; manufacturing substantially completed VYD2311 first‑in‑human safety and PK with IM half‑life ~76 days; dose modeling supports long‑interval IM dosing Strengthening dataset
Macro/tariffsN/ACompany “well‑insulated from potential tariffs and most‑favored‑nation impact” on PEMGARDA Risk manageable
Long COVIDN/ASPEAR Study Group formed in July 2025 to assess mAb therapy for Long COVID and post‑vaccination syndromes New initiative

Management Commentary

  • “We believe we are entering a remarkable period of change for the company that points toward an exciting future… we expect to move quickly to cement our position as the leading provider of monoclonal antibody technology for Americans in need of COVID‑19 protection.” — Marc Elia, Chairman .
  • “While the second quarter PEMGARDA growth was modest, the base business is growing along with our internal commercial capabilities… we look forward to additional upcoming anticipated milestones including identification of a potentially best‑in‑class RSV candidate in Q3 2025… and advancement of our efforts to support the Long COVID community.” — Bill Duke, CFO .
  • “FDA advised that a single, Phase 2/3 randomized, double‑blind, placebo‑controlled trial… could support a BLA submission for VYD2311… subject to agreement on safety database size and pending full protocol review.” — Press release excerpt .

Q&A Highlights

  • No Q2 2025 earnings call transcript was available in our document corpus or via targeted search; Q&A specifics cannot be validated. We relied on the 8‑K press release, exhibits, and the August corporate deck for qualitative themes .

Estimates Context

MetricConsensus EstimateActual
Revenue ($USD)$23.161M*$11.786M
EPS ($USD)-$0.023*-$0.12
# of Estimates (Revenue)3*—
# of Estimates (EPS)3*—
  • Outcome: Revenue and EPS both missed consensus materially; Street likely revisits commercialization trajectory and seasonality expectations (S&P Global).
  • Where estimates may adjust: Lower near‑term revenue run‑rate assumptions and wider loss per share in low transmission quarters; potential upward revisions later if respiratory seasonality inflects as management anticipates [Values retrieved from S&P Global].

Key Takeaways for Investors

  • Q2 was a clear miss vs Street on both revenue and EPS; sequential growth was modest, reflecting seasonality and ongoing commercialization ramp of PEMGARDA in a low‑transmission quarter [Values retrieved from S&P Global].
  • Regulatory pathway is the main equity catalyst: FDA alignment on a compact single Phase 2/3 trial for VYD2311 materially clarifies approval logistics and timeline; watch for IND filing, protocol finalization, and trial initiation updates .
  • VYD2311’s ~76‑day IM half‑life and favorable safety profile support the vaccine‑alternative narrative; dose modeling points to long‑interval dosing and broader market potential if efficacy is confirmed .
  • Liquidity is constrained but flexible: $34.9M cash plus a $30M SVB facility provide runway; continued opex moderation is critical to bridge to seasonal revenue uplift and pipeline milestones .
  • Commercial execution indicators (guideline support, field force expansion) are constructive; monitor payer pathways, protocol adoption in major networks, and reordering growth into fall/winter .
  • Near‑term milestones (RSV in Q3, measles by YE25) can broaden the narrative beyond COVID and offer optionality; execution pace and regulatory interactions will drive sentiment .
  • Trading lens: Shares reacted negatively on the miss; risk/reward hinges on VYD2311’s clinical/regulatory progress and confirmation of seasonal revenue inflection for PEMGARDA .

Footnote: *Values retrieved from S&P Global.